Eurofins-Cerep SA is a leading company in the field of drug discovery services. Their core values include excellence, innovation, and customer focus. Eurofins-Cerep SA aims to provide high-quality research solutions to pharmaceutical and biotech industries, helping them accelerate the drug discovery process. With a commitment to scientific expertise and market leadership, Eurofins-Cerep SA constantly strives to deliver reliable and timely results. Their corporate philosophy revolves around collaboration, integrity, and continuous improvement, ensuring a strong foundation for their clients' success. By integrating cutting-edge technologies and a customer-centric approach, Eurofins-Cerep SA remains a trusted partner for companies seeking efficient and effective drug discovery solutions.

Eurofins-Cerep SA is primarily present in France, where its headquarters is located. As a leading global provider of discovery services, Eurofins-Cerep SA also has a significant presence in other countries and regions including the United States, India, China, Germany, and the United Kingdom. With its expansive global network, Eurofins-Cerep SA is able to cater to the research and development needs of clients worldwide, offering innovative solutions in drug discovery and development.

Eurofins-Cerep SA, a leading drug discovery services company, has achieved several significant milestones. Over the years, the company has established a strong reputation in the pharmaceutical industry. Eurofins-Cerep SA has successfully provided high-quality drug discovery solutions, including in vitro and in vivo assays, ADME-Tox profiling, and medicinal chemistry optimization. Additionally, they have developed innovative technologies, such as their patented ChemPrint(R) platform, which enables efficient screening of large compound libraries. The company has also forged strategic partnerships with key players in the pharmaceutical and biotech sectors, further enhancing its capabilities and global reach. Eurofins-Cerep SA's commitment to excellence and continuous innovation has solidified its position as a trusted and respected name in the industry.

Eurofins-Cerep SA is a leading company in the field of in vitro screening for drug discovery. Established in 1991, Eurofins-Cerep has built a strong reputation for its expertise in high-throughput screening and pharmacology services. The company offers a comprehensive range of solutions to pharmaceutical and biotechnology industries, helping them to identify potential drug candidates and optimize the development process. Eurofins-Cerep's extensive databases and advanced technologies enable efficient compound profiling and target validation, contributing to the progress of drug research and development. With its rich history and continuous dedication to innovation, Eurofins-Cerep is a trusted partner in the pharmaceutical industry.

The main competitors of Eurofins-Cerep SA in the market are companies like Charles River Laboratories International Inc., WuXi AppTec Co Ltd, Covance Inc., and Evotec SE. These companies also operate in the contract research organization (CRO) industry, offering similar services in drug discovery and development. With its strong position in the market, Eurofins-Cerep SA faces competition from these reputable players.

Eurofins-Cerep SA is primarily active in the pharmaceutical and biotechnology industries.

The business model of Eurofins-Cerep SA is focused on providing drug discovery and development services to the pharmaceutical and biotechnology industry. Eurofins-Cerep offers a wide range of services such as target validation, screening, and lead optimization, enabling clients to make informed decisions in the development of new drugs. With its expertise in high-throughput screening, Eurofins-Cerep helps pharmaceutical companies identify and optimize potential drug candidates efficiently. By combining bioanalytical methods with computational modeling, Eurofins-Cerep contributes to the acceleration of drug discovery processes. Eurofins-Cerep strives to be a trusted partner in drug research, offering innovative solutions to meet the evolving needs of the industry.

Eurofins-Cerep에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

Eurofins-Cerep에 대한 현재 KUV는 계산할 수 없습니다.

Eurofins-Cerep에 대한 AlleAktien 품질 점수는 7/10입니다.

Eurofins-Cerep에 대한 현재 매출은 계산할 수 없습니다.

Eurofins-Cerep의 현재 이익을 계산할 수 없습니다.

Eurofins-Cerep SA is a leading provider of biological screening services and offers a wide range of in vitro testing systems and biological assays. The company works closely with customers in the pharmaceutical, biotechnology, and agrochemical industries to assist them in identifying and validating target molecules. Eurofins-Cerep SA covers various areas including drug development, toxicology, functional genomics, and drug safety. Each of these divisions includes specific test systems and services tailored to the needs of customers. In the drug development sector, the company offers high-throughput screenings, in vitro assays, cloning services, cell line studies, receptor expression analysis, and many other services. The toxicology division provides a comprehensive portfolio of in vitro and in vivo tests, as well as angiogenic and biomarker studies. The drug safety group offers a broad range of pharmacological and toxicological studies monitoring the safety of drugs during clinical development and market launch. Another important area of Eurofins-Cerep SA is the functional genomics division, which specializes in genome-wide assays and gene expression analysis. Genomics technology is a critical component of modern drug development, and Eurofins-Cerep SA offers its customers leading technologies and services in this field. The company also collaborates with customers in the agrochemical industry, offering them a wide range of services including metabolomics studies, in vitro and in vivo screenings, toxicity testing, and residue analysis. The portfolio of Eurofins-Cerep SA includes a range of products including assay kits, antibodies, cell lines, plasmids, and other reagents that allow customers to conduct their own in vitro tests. These products are a valuable addition to the company's services, expanding the offerings even further. Overall, Eurofins-Cerep SA is a leading company in the biological screening industry, offering its customers a wide range of services and products tailored to their specific needs. The company works closely with customers to help them identify target molecules and develop new drugs and agrochemicals, playing a crucial role in the healthcare and agricultural industries.

Eurofins-Cerep은(는) 연간 번의 배당을 통해 0 EUR의 배당금을 지급합니다.

Eurofins-Cerep의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Eurofins-Cerep의 ISIN은 FR0013256518입니다.

Eurofins-Cerep의 WKN은 A2DT0B입니다.

Eurofins-Cerep의 티커는 ALECR.PA입니다.

지난 12개월 동안 Eurofins-Cerep은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Eurofins-Cerep은(는) 0 EUR의 배당금을 지급할 것으로 예상됩니다.

Eurofins-Cerep의 현재 배당 수익률은 입니다.

Eurofins-Cerep은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Eurofins-Cerep은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 EUR의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Eurofins-Cerep은 '건강' 섹터에 속합니다.

Eurofins-Cerep의 마지막 배당금을 0 EUR만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Eurofins-Cerep는 0 EUR를 배당금으로 지급했습니다.

Eurofins-Cerep의 배당금은 EUR에 지급됩니다.